21753-19-5

Usage

Uses

Used in Organic Synthesis:
Nα-Tosyl-D-α,β-diaminopropionic Acid is used as a synthetic building block for the development of complex organic molecules. Its unique structure and reactivity make it a versatile component in the synthesis of a wide range of compounds, including pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Nα-Tosyl-D-α,β-diaminopropionic Acid is used as a key intermediate in the synthesis of various therapeutic agents. Its incorporation into drug molecules can enhance their pharmacological properties, such as potency, selectivity, and bioavailability, leading to the development of more effective treatments for a variety of diseases.
Used in Agrochemical Industry:
Nα-Tosyl-D-α,β-diaminopropionic Acid also finds application in the agrochemical industry, where it is employed in the synthesis of novel pesticides and other crop protection agents. Its unique chemical properties allow for the creation of innovative molecules with improved efficacy and selectivity, contributing to more sustainable and environmentally friendly agricultural practices.
Used in Research and Development:
In the field of research and development, Nα-Tosyl-D-α,β-diaminopropionic Acid serves as an important tool for chemists and biologists working on the discovery and optimization of new molecules with potential applications in various industries. Its availability and reactivity make it a valuable asset in the pursuit of scientific advancements and the development of innovative solutions to complex problems.

InChI:InChI=1/C10H14N2O4S/c1-7-2-4-8(5-3-7)17(15,16)12-9(6-11)10(13)14/h2-5,9,12H,6,11H2,1H3,(H,13,14)

Upstream product

• 36212-66-5 N²-(toluene-4-sulfonyl)-L-asparagine 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 21760-84-9 N^α-Tosyl-N^β-cyanmethyl-L-α,β-diamino-propionsaeure 
• 16947-86-7 N^α-Tosyl-N^β-(tert-butpxycarbonyl)-L-α,β-diamonopropionic acid 
• 84856-37-1 Nβ-(5-amino-4-chloro-6-pyrimidinyl)-α-tosyldiaminopropionic acid 
• 74536-29-1 (S)-2-amino-3-((tert-butoxycarbonyl)amino)propanoic acid 
• 90263-74-4 (3S)-3-p-tolylsulphonamidoazetidin-2-one 
• 96846-01-4 N²-<(4-methylphenyl)sulfonyl>-2-amino-3-<<(methylamino)carbonyl>amino>propanoic acid 
• 1186-65-8 (S)-2,3-diaminopropanoic acid hydrobromide 
• 199853-68-4 (S)-3-(3-Methyl-benzoylamino)-2-(toluene-4-sulfonylamino)-propionic acid 
• 64-18-6 formic acid 
• 70-55-3 toluene-4-sulfonamide 
• 251553-60-3 2(S)-[(p-toluenesulfonyl)amino]-3-[[[5,6,7,8-tetrahydro-4-oxo-5-[2-(pyridin-4-yl)ethyl]-4H-pyrazolo[1,5-a][1,4]diazepin-2-yl]carbonyl]amino]propionic acid benzyl ester 
• 169604-92-6 (S)-3-tert-Butoxycarbonylamino-2-(toluene-4-sulfonylamino)-propionic acid methyl ester 
• 80312-73-8 (S)-3-amino-2-(4-toluenesulfonyl)amino-1-propanol 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS THAT BLOCK THE EFFECTS OF ADVANCED GLYCATION END PRODUCTS (AGE)

The present invention relates to novel compounds of Formula (Ia) or (Ib), their pharmaceutically acceptable salts and pharmaceutically acceptable compositions containing them. Formula (Ia), or Formula (Ib) in the above formulae L represents Formula (I), Formula (II) or -(CH2)1- Q represents Formula (III), or Formula (IV). The present invention also relates to a process for the preparation of the above said novel compounds, their pharmaceutically acceptable salts and pharmaceutical compositions containing them. The present invention also relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory responses in tissues, including endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. The present invention also relates to compounds that act as modulators of Perlecan activity and expression. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating heparan sulfate proteoglycans (HSPG) such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as stenosis, restenosis, neointimal hyperplasia, and atherosclerosis. The compounds of Formula (I) are also useful for the treatment and/or prevention of cancer. The types of cancers include melanoma, prostate, leukemia, lymphoma, non-small lung cancers, cancer of the central nervous system, breast, colon, ovarian or renal cancer.

A highly convergent synthesis of a fibrinogen receptor antagonist

A practical multikilogram synthesis of 2(S)-[(p-toluenesulfonyl)amino]- 3-[[[5,6,7,8-tetrahydro-4-oxo-5-[2-(piperidin-4-yl)ethyl]-4H-pyrazolo[1,5- α][1,4]diazepin-2-yl]carbonyl]amino]propionic acid pentahydrate (1), an oral fibrinogen receptor antagonist, is described. The nine-step convergent process, which afforded 1 in 37% overall yield, included pyrazole 5a and N- tosylaminoalanine 16 as key fragments. Pyrazole 5a was obtained from pyrazole-3,5-dicarboxylic acid by esterification with MeOH, alkylation/cyclization with 3-bromopropylamine, and Michael addition with 4- vinylpyridine. N-Tosylaminoalanine 16 was prepared by tosylation of asparagine, Hofmann reaction, and benzyl esterification. Saponification of pyrazole 5a, coupling of the acid with N-tosylaminoalanine 16, and Pd- catalyzed hydrogenolysis and pyridine reduction completed the synthesis.

Fibrinogen receptor antagonists

Fibrinogen receptor antagonists having the structure, for example, of STR1 for example STR2

Asymmetric synthesis of (R)-6-amino-1-methyl-4-(3-methyl- benzyl)hexahydro-1H-1,4-diazepine from L-asparagine

An efficient asymmetric synthesis of (R)-6-amino-1-methyl-4-(3- methylbenzyl)hexahydro-1H-1,4-diazepine [(R)-2] which serves as the amine part of (R)-1, a potent and selective 5-HT3 receptor antagonist, is described. Formation of the hexahydro-

Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists

The synthesis and pharmacological evaluation of 5 (L-738,167), a potent, selective non-peptide fibrinogen receptor antagonist is reported. Compound 5 inhibited the aggregation of human gel-filtered platelets with an IC50 value of 8 nM and was found to be >33000-fold less effective at inhibiting the attachment of human endothelial cells to fibrinogen, fibronectin, and vitronectin than it was at inhibiting platelet aggregation. Ex vivo platelet aggregation was inhibited by >85% 24 h after the oral administration of 5 to dogs at 100 μg/kg. The extended pharmacodynamic profile exhibited by 5 appears to be a consequence of its high-affinity binding to GPIIb/IIIa on circulating platelets and suggests that 5 is suitable for once-a-day dosing.

Facile acid-promoted decarboxylation of a macrocyclic complex. Crystal structure of [6,14-diacetyl-7,13-dimethyl-1,4,8,12-tetraazacyclopentadeca-1(15),5,7,13- tetraen-2-olato]nickel(II)

A new chiral tetradentate compound has been prepared from (S)-2,3-diaminopropanoic acid and 3-ethoxymethylenepentane-2,4-dione and the corresponding nickel(II) and palladium(II) complexes have been characterized. The racemic form of the nickel(II) complex

Synthesis of a Monocyclic β-Lactam Stereospecifically Labelled at C-4

In connection with biosynthetic studies, the β-lactams (5; 4-HR = 2H) and (5; 3-H = 4-HS = 2H) have been synthesized.The 1H and 2H n.m.r. spectra of these compounds confirm the assignment of the stereochemistry to the two hydrogens at C-4 of monocyclic β-lactams such as nocardicin A.Samples of the amino-acid L-asparagine stereospecifically labelled at C-3 have been made in the course of this work.

Effects of arginine homologues and other guanidino compounds on the ATP level and glucose oxidation in isolated fat cells

The arginine homologues 2 amino 3 guanidinopropionic acid, 2 amino 4 guanidinobutyric acid and 2 amino 6 guanidinocaproic acid (= homoarginine) were synthesized and transformed into their methyl esters. The latter, together with arginine methyl ester, arg